AC Immune to Host Key Opinion Leader Meeting on Abeta Oligomers in Alzheimer's Disease (AD) and the Involvement of Other Misf...
November 01 2018 - 5:01AM
- Key Opinion Leaders to discuss emerging concepts in the
development of therapies for Alzheimer's Disease and other
neurodegenerative diseases
- Meeting scheduled for November 5, 2018, from 12:00pm -
2:00pm ET
- AC Immune's Nasdaq Opening Bell ceremony takes place same
day at 9:30am ET
Lausanne, Switzerland, November 1, 2018 -
AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage
biopharmaceutical company with a broad pipeline focused on
neurodegenerative diseases, today announced that it will host a Key
Opinion Leader (KOL) luncheon meeting on emerging concepts in the
development of therapies for Alzheimer's Disease (AD) and other
neurodegenerative diseases. The meeting is scheduled for November
5, 2018, from 12.00pm to 2:00pm ET at the Nasdaq MarketSite, 4
Times Square, New York.
At 9:30am ET that morning AC Immune's CEO
Professor Andrea Pfeifer will ring the Opening Bell signaling the
start of trading on Nasdaq.
The luncheon meeting will feature presentations
by two KOLs who have played important roles in neurodegenerative
disease research: Professor Michael W. Weiner, University of
California San Francisco School of Medicine and Professor John Q.
Trojanowski, Perelman School of Medicine, University of
Pennsylvania.
Professor Weiner, a leading expert in brain
imaging and biomarkers, will discuss recent developments in our
understanding of the ß-amyloid cascade and will highlight the
important role of biomarkers for early diagnostic and treatment of
AD. He will also discuss the additional role of tau in disease
spreading and progression. The talk of Professor Trojanowski will
highlight additional protein targets such as alpha-synuclein and
TDP-43 in the etiology of neurodegenerative diseases, including AD,
Parkinson's Disease and neuro-orphan diseases such as Down
Syndrome, Progressive Supranuclear Palsy and Frontotemporal
Dementia.
Professor Andrea Pfeifer, CEO of AC Immune, will
conclude the session with a corporate overview of the Company's
early and late stage programs, highlighting the value of AC
Immune's technologies that target such misfolded proteins, as well
as the role of diagnostics in the quest for effective therapies for
Alzheimer's disease, Parkinson's and neuro-orphan diseases.
A Q&A session with the featured KOLs and the
management will follow the presentations.
A live webcast will be available on the Investor
Page of AC Immune's website and will be available on the Company's
website for 90 days following the event.
KOL Biographies
Michael W. Weiner M.D.Professor,
Department of RadiologyUniversity of California San Francisco
School of Medicine
Dr. Weiner is Professor in Residence in
Radiology and Biomedical Imaging, Medicine, Psychiatry, and
Neurology at the University of California, San Francisco. He is
Principle Investigator of the Alzheimer's Disease Neuroimaging
Initiative, which is the largest observational study in the world
concerning Alzheimer's Disease. He is the former Director of the
Center for Imaging of Neurodegenerative Diseases (CIND) at the San
Francisco Veterans Affairs Medical Center. During the past 25 years
he has worked to develop and optimized the use of MRI, PET, and
blood based biomarker methods to diagnose Alzheimer's disease and
other neurodegenerative disorders. Dr. Weiner's research also
focuses on monitoring effects of treatment to slow progressions in
Alzheimer's disease, and detecting Alzheimer's disease early in
patients who are not demented, but risk subsequent development of
dementia.
John Q. Trojanowski M.D.,
Ph.D.Co-Director Center for Neurodegenerative ResearchPerelman
School of MedicineUniversity of Pennsylvania
Dr. Trojanowski obtained his MD/PhD in 1976 from
Tufts University, did his internal medicine internship at Mt.
Auburn Hospital, his pathology and neuropathology at Massachusetts
General Hospital and the University of Pennsylvania Perelman School
of Medicine where he joined the faculty in 1981. He is Professor of
Pathology and Laboratory Medicine, Director of the NIA Alzheimer's
Disease Center, the National Institute of Neurological Disorders
(NINDS) Morris K. Udall Parkinson's Disease Center, and the
Institute on Aging. His research focuses on Alzheimer's (AD) and
Parkinson's (PD) disease, amyotrophic lateral sclerosis (ALS),
frontotemporal degeneration (FTD) which led to the discovery of the
major disease proteins in these disorders.
About AC Immune AC Immune is a
clinical-stage Swiss-based biopharmaceutical company, listed on
NASDAQ, which aims to become a global leader in precision medicine
for neurodegenerative diseases. The Company designs, discovers and
develops therapeutic as well as diagnostic products intended to
prevent and modify diseases caused by misfolding proteins. AC
Immune's two proprietary technology platforms create antibodies,
small molecules and vaccines designed to address a broad spectrum
of neurodegenerative indications, such as Alzheimer's disease (AD).
The Company's pipeline features nine therapeutic and three
diagnostic product candidates - with five product candidates
currently in clinical trials. The most advanced of these is
crenezumab, a humanized anti-amyloid-ß monoclonal IgG4 antibody
that targets monomeric and aggregated forms of amyloid-ß, with
highest affinity for neurotoxic oligomers. Crenezumab is currently
in two Phase 3 clinical studies for AD, under a global program
conducted by the collaboration partner Roche/Genentech. Other
collaborations include Biogen, Janssen Pharmaceuticals, Nestlé
Institute of Health Sciences, Piramal Imaging and Essex
Bio-Technology.
Forward looking statements This press
release contains statements that constitute "forward-looking
statements" within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934.
Forward-looking statements are statements other than historical
fact and may include statements that address future operating,
financial or business performance or AC Immune's strategies or
expectations. In some cases, you can identify these statements by
forward-looking words such as "may," "might," "will," "should,"
"expects," "plans," "anticipates," "believes," "estimates,"
"predicts," "projects," "potential," "outlook" or "continue," and
other comparable terminology. Forward-looking statements are based
on management's current expectations and beliefs and involve
significant risks and uncertainties that could cause actual
results, developments and business decisions to differ materially
from those contemplated by these statements. These risks and
uncertainties include those described under the captions "Item 3.
Key Information-Risk Factors" and "Item 5. Operating and Financial
Review and Prospects" in AC Immune's Annual Report on Form 20-F and
other filings with the Securities and Exchange Commission.
Forward-looking statements speak only as of the date they are made,
and AC Immune does not undertake any obligation to update them in
light of new information, future developments or otherwise, except
as may be required under applicable law. All forward-looking
statements are qualified in their entirety by this cautionary
statement.
For further information, please
contact:
In EuropeBeatrix BenzAC Immune Corporate Communications
Phone: +41 21 345 91 34E-mail: beatrix.benz@acimmune.com |
In the USLisa SherAC Immune Investor Relations Phone: +1 970
987 26 54E-mail: lisa.sher@acimmune.com |
Nick Miles/Toomas KullCabinet Privé de Conseils s.a.Phone: +41 22
552 46 46 E-mail: miles@cpc-pr.com kull@cpc-pr.com |
Ted AgneThe Communications Strategy Group Inc.Phone: +1 781 631
3117E-mail: edagne@comstratgroup.com |
AC Immune (NASDAQ:ACIU)
Historical Stock Chart
From Mar 2024 to Apr 2024
AC Immune (NASDAQ:ACIU)
Historical Stock Chart
From Apr 2023 to Apr 2024